Abstract | INTRODUCTION: METHODS: This study included women with T2DM, without a history of cancers, and followed up for more than one year from the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) for the period 1998-2014. The dataset was structured using a person-time approach, where the cumulative medication usage was annually updated for each person. The extended Cox proportional hazards models were employed, reporting adjusted hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: During a median follow-up of 5 years, 515 of 29,498 women received a breast cancer diagnosis. Each additional year of metformin or statins use corresponded to a decrease in breast cancer incidence, while the magnitude attenuated over time. Noteworthily, statin use modified the effect of metformin on breast cancer incidence. For instance, after 5 years of follow-up, one-year increase of metformin use among women who used statins for 3 years was linked to a substantially reduced breast cancer risk (HR, 95% CI: 0.88, 0.84-0.93), however, there was no significant decrease in risk for those non- statins users (HR, 95% CI: 0.96, 0.89-1.04). CONCLUSIONS:
|
Authors | Fan Zhang, Geertruida H de Bock, Gijs W Landman, Qingying Zhang, Grigory Sidorenkov |
Journal | Cancer & metabolism
(Cancer Metab)
Vol. 12
Issue 1
Pg. 12
(Apr 12 2024)
ISSN: 2049-3002 [Print] England |
PMID | 38610045
(Publication Type: Journal Article)
|
Copyright | © 2024. The Author(s). |